Glycoprotein IIb/IIIa receptor antagonists. Clinical pharmacology in cardiovascular diseases of aging

Drugs and Aging

Volumn 15, Issue 3, 1999, Pages 207-218

  Sebastian, Martin ^a   Makkar, Raj ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; DAZOXIBEN; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; KETANSERIN; LAMIFIBAN; LEFRADAFIBAN; LOTRAFIBAN; MONOCLONAL ANTIBODY; N ETHYL N [4 (4 PIPERIDINYL)BUTYRYL]GLYCYLASPARTYL 3 CYCLOHEXYLALANINAMIDE; ORBOFIBAN; PHYTOMENADIONE; RIDOGREL; SIBRAFIBAN; STREPTOKINASE; TICLOPIDINE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; WARFARIN; XEMILOFIBAN;

ACUTE HEART INFARCTION; AGED; AGING; BLEEDING; BLOOD DISEASE; BLOOD VESSEL COMPLIANCE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG SYNTHESIS; DRUG TARGETING; ENDOTHELIUM INJURY; GLANZMANN DISEASE; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUROENDOCRINE SYSTEM; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN CROSS LINKING; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

AGE FACTORS; AGING; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; FIBRINOLYTIC AGENTS; FORECASTING; HUMANS; PHARMACOLOGY, CLINICAL; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE;

EID: 0032884960     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199915030-00004     Document Type: Review

References (75)

1. Cannon LA, Marshall JM. Cardiac disease in the elderly population. Clin Geriatr Med 1993; 9: 499-525
2. American Heart Association. Heart and stroke facts. Dallas (TX): American Heart Association National Center, 1996
3. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991; 121: 951-7
4. Krumholz HM, Friesinger GC, Cook EF, et al. Relationship of age with eligibility for thrombolytic therapy and mortality among patients with suspected acute myocardial infarction. J Am Geriatr Soc 1994; 42: 127-31
5. Weisfeldt ML, Lakatta EG, Gerstenblith G. Aging, and the heart. In: Braunwald E, editor. Heart disease: a textbook of cardiovascular medicine. 4th ed. Philadelphia (PA): WB Saunders, 1992: 1664
6. Suhasakul Y, Edwards WD, Naessans JM, et al. Age-related changes in aortic and mitral valve thickness: implications for two-dimensional echocardiography based on an autopsy study of 200 normal human hearts. Am J Cardiol 1988; 62: 424-30
7. Cefalu CA, Burris JF. Cardiovascular disease in the elderly. Compr Ther 1996; 22: 509-14
8. Spirito P, Maron BJ. Influences of aging on Doppler echocardiographic indices of left ventricular diastolic function. Br Heart J 1988; 59: 672-9
9. Belz GG. Elastic properties and Windkessel function of the human aorta. Cardiovase Drugs Ther 1995; 9: 73-83
10. Duncan AK, Vittone J, Fleming KC, et al. Cardiovascular disease in elderly patients. Mayo Clin Proc 1996; 71: 184-96
11. Dohi Y, Kojima M, Sato K, et al. Age-related changes in vascular smooth muscle and endothelium. Drugs Aging 1995; 7: 278-91
12. Vericel E, Rey C, Haond P, et al. Age-related changes in arachadonic acid peroxidation and glutathione-peroxidase activity in human platelets. Prostaglandins 1992; 43: 75-85
13. Benjamen EJ, Levy D, Vaziri S, et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham heart study. JAMA 1994; 271: 840-4
14. Wei JY, Gersh BJ. Heart disease in the elderly. Curr Probl Cardio 1987; 12: 1-65
15. Handin RI. Disorders of the platelet and vessel wall. In: Wilson JD, Braunwald E, Isselbacher KJ, et al., editors. Harrison's principles of internal medicine. 12th ed. New York: McGraw-Hill, 1991: 1500
16. White HD. Unmet therapeutic needs in the management of acute ischemia. Am J Cardiol 1997; 80 (4A): 2B-10
17. Wagner CL, Mascelli MA, Neblock DS, et al. Analysis of GP IIb/IIIa number by quantification of 7E3 binding to human platelets. Blood 1996; 88: 907-14
18. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-9
19. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997; 80 (4A): 11B-20
20. Ginsberg MH, Du X, Plow EF. Inside-out integrin signalling. Curr Opin Cell Biol 1992; 4: 766-71
21. Ruoslahti E, Piersbacher MD. Arg-gly-asp: a versatile cell recognition signal. Cell 1986; 44: 517-8
22. Théroux P. Antiplatelet therapy: do the new platelet inhibitors add significantly to the clinical benefits of aspirin? Am Heart J 1997; 134: S62-70
23. Weitz. JI, Califf RM, Ginsberg JS, et al. New antithrombotics. Chest 1995; 108: 471S-85
24. Ikeda Y, Handa M, Kawano K, et al. The role of von Willebrand factor and tibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991; 87: 1234-40
25. Faster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994; 90: 2126-46.
26. Mizuna K, Satomura K, Miyamoto A, et al. Angioscopic evaluation of coronary artery thrombi in acute coronary syndromes. N Engl J Med 1992; 326: 287-91
27. Faster V. Badimon L, Badimon JJ, et al. This pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-50, 310-8
28. Makkar RR, Litvack F. Eigler NI., et al. Effects of GP IIb/IIIa receptor monoctonal antibody (7E3), hepurin and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis. Circulation 1997; 95: 1015-21
29. Mak KH, Belli G, Ellis SG, et al. Subacute stent thrombosis: evolving issues and current concepts. J Am Coll Cardiol 1996; 27: 494-503
30. Antiplatelet Trilists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106
31. Coller BS, Peerschke EI, Scudder LE, et al. A murine monoclonat antibody that completely blocks the binding of Tibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-38
32. Quinn MB, Fitzgerald DJ. Long-term administration of glycoprotein IIb/IIIa antagonists. Am Heart J 1998; 135: S113-8
33. Coller BS. GPIIb/IIIa antigonists: pathophysiological and therapeutic insights from studies of c7E3 Fab. Thromb Haemost 1997; 78: 730-5
34. Scarborough RM, Naughton MA, Teng W. Design of potent and specific integrin antagonists with high specificity for glycoprotein IIb/IIIa. J Biol Chem 1993; 268: 1066-73
35. Peerlinck K, DeLepeleire I, Goldberg M, et al. MK-383 (L700,462), a selective non-peptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 1993; 88: 1512-7
36. Cox D, Aoki T, Seki J, et al. The pharmacology of the integrins. Med Res Rev 1994; 14: 195-228
37. Teheng JE, Ellis SG, George BS, et al. Pharmacodynamics of enimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994; 90: 1757-64
38. Brown SL, Lundgren CH, Nordt T, et al. Stimulation of migration of human aortic smooth muscle cell by vitronectin: implications for atheroselerosis. Cardiovasc Res 1994; 28: 1815-20
39. Coller BS Monitoring platelet GP IIb/IIIa therapy. Circulation 1998; 97: 5-9
40. Théroux P. Oral inhibitors of platelet membrane receptor IIb/IIIa in clinical cardiology: issues and opportunities. Am Heart J 1998; 135: S107-12
41. Aguirre I V, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa in patients undergoing percutaneous intervention. Circulation 1995; 91: 2882-90
42. Ferguson JJ, Kerciakis DJ, Adgey AAJ, et al. Safe use of GP IIb/IIIa inhibitors. Eur Heart J 1998: 19 Suppl.: D40-51
43. Berkowitz SD, Harrington RA, Rund MM, et al. Acute profound thrombocytopenia after c7E3 Fab (abeiximab) therapy. Circulation 1997; 95: 809-13
44. Faulds D, Sorkin EM. Abciximab (c7EH Fab): a review of its pharmacology and therapeutic potential in ischacmic heart disease. Drugs 1994; 48: 583-98
45. Coller BS, Folts JD, Scudder LE, et al. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 1986: 68: 783-6
46. Hanson SR, Pareti FI, Ruggeri ZM, et al. Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon. J Clin Invest 1988;77:670-7
47. Ellis SG, Navetta FI, Tcheng JT, et al. Safety and antiplatelet effect of murine monoclonal antibody c7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing coronary angioplasty: an initial experience. Coron Artery Dis 1993; 4: 167-75
48. Simoons ML, de Boer MJ, van den Brand MJ, et al. Randomized trial of a GPIIb/IIIa platelet blocker in refractory unstable angina. Circulation 1994; 89: 596-603
49. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61
50. Topol EJ, Ferguson JJ, Weisman HF, the EPIC Investigator Group, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief Integrin β3 blockade with percutaneous intervention. JAMA 1997; 278: 479-84
51. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet 1997; 349: 1429-35
52. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96
53. The IMPACT II Investigators. Randomised placebo-controlled trial of eptifibatide on complications of percutaneous coronary intervention. Lancet 1997; 349; 1422-8
54. The RESTORE Investigators. The effects of glycoprotein IIb/IIIa blockage tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445-53
55. The EPISTENT Investigators. Randomised placebo controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIablockade. Lancet 1998; 352: 87-92
56. The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet IIb/IIIa inhibitor), heparin or both in unstable angina. Circulation. 1998; 97: 2386-95
57. The PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-505
58. The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med 1998; 338: 1488-97
59. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-43
60. Topol EJ. Toward a new frontier in myocardial reperfusion therapy. Circulation 1998; 97: 211-8
61. Fitzgerald DJ, Catella F, Roy L, et al. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. N Engl J Med 1988; 77: 142-50
62. Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody c7E3 Fab after thrombolytic therapy: results of the thrombolysis and angioplasty in myocardial infarction (TAMI) 8 pilot study. J Allergy Clin Immunol 1993; 22: 381-9
63. Ohman EM, Kleiman NS, Gacioch G, the IMPACT-AMI Investigators, et al. Combined accelerated tissue plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Circulation 1997: 95: 846-54
64. Moliterno DJ, Harrington RA, Krucoff MW, the PARADIGM Investigators, et al. More complete and stable reperfusion with platelet IIb/IIIa antagonism plus thrombolysis for AMI: the PARADIGM Trial [abstract]. Circulation 1996; 94 Suppl.1:553
65. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebocontrolled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998; 98 (8): 734-41
66. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase or both on coronary artery patency, ventricular function and survival after myocardial infarction. N Engl J Med 1993; 329; 1615-22
67. Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990; 322: 33-42
68. Jan IK, Gold HK, Ziskind AA, et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: a possible explanation for resistance to coronary thrombolysis. Circulation 1989:79:920-8
69. Gold HK, Garabedian HD, Dinsmore RE, et al. Restoration of coronary flow in myocardial infarction by chimeric 7E3 antibody without exogenous plasminogen activators: observations in animals and humans. Circulation 1997; 95: 1755-9
70. Moliterno DJ, Topol EJ. Conjunctive use of platelet glycoprotein IIb/IIIa antagonists and thrombolytic therapy for acute myocardial infarction. Thromb Haemost 1997; 78: 214-9
71. van den Merkhof LFM, Zijlstra F, Olsson H, et al. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1999; 33: 1528-32
72. Makkar R, Goff B, Eigler NE, et al. The effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: results of ReoMI Pilot Study. Cathet Cardiovasc Diagn. In press
73. Ferguson JJ, Lau TK. New antiplatelet agents for acute coronary syndromes. Am Heart J 1998; 135: S194-200
74. Chronos N, Vahanian A, Betriu A, et al. Use of abciximab in interventional cardiology. Eur Heart J 1998; 19 Suppl.: D31-9
75. Goklaney AK, Murphy JD, Hillegass WB. Abciximab therapy in percutaneous intervention: economic issues in the United States. Eur Heart J 1998; 19 Suppl.: D52-8